Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma’s latest mouse study has given strong results for its pancreatic cancer treatment drug
  • The drug showed a stronger reduction in tumour growth compared to the current standard pancreatic cancer treatment
  • The drug was studied by implanting human cancer cells into mice and treating the tumours
  • Human trials are yet to be conducted
  • Starpharma’s share price is down 1.72 per cent today, with shares worth $1.14 each

Starpharma’s latest testing shows strong results for its pancreatic cancer treatment drug.

The product, known as DEP gemcitabine, builds on Starpharma’s DEP drug delivery technology, which is designed to improve the efficacy of other cancer treatment medicines.

This latest study proved DEP gemcitabine to be more effective than the current standard pancreatic cancer therapy, which is a drug called Gemzar used either alone or in combination with Abraxane and developed by U.S. pharmaceutical giant Eli Lilly and Co.

Lilly’s Gemzar had peak sales of US$1.7 billion, and the company’s market cap is valued at US$108 billion.

According to Starpharma, DEP gemcitabine showed “significantly enhanced anti-tumour activity” when compared to Gemzar — both by itself and in combination with Abraxane.

Starpharma CEO Dr Jackie Fairley said: “We are delighted to be progressing yet another internal candidate through the development and to have achieved such impressive results in this important cancer type with otherwise limited options for patients.”

DEP gemcitabine is one of several DEP potential products in preclinical development by Starpharma.

The DEP gemcitabine study was performed by implanting human pancreatic cancer cells in a mouse and assessing the efficacy of Starpharma’s products on these self-grown tumours.

In these studies, DEP gemcitabine by itself saw increased anti-tumour activity compared to Gemzar, and tumour growth flatlined by the 30th day when used in combination with Abraxane.

Human trials, however, are yet to be conducted.

In light of these results, Starpharma has filed for a patent for DEP gemcitabine to protect it through to 2040.

Starpharma’s share price is down 1.72 per cent today, with shares worth $1.14 each at 2:21 pm AEDT. Starpharma’s market cap is valued at $427.79 million.

SPL by the numbers
More From The Market Herald

" Orthocell’s (ASX:OCC) rotator cuff tendon treatment proves successful

Orthocell’s (OCC) latest study results have revealed OrthoATI is much more effective than steroid injection when treating rotator cuff tendinopathy with intrasubstance tendon
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) posts “remarkable” Zantrene results

Race Oncology (RAC) has released further interim results from the Zantrene preclinical heart safety research program.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).